GlaxoSmithKline Q2 Results: Profit increases by 16%, reaching ₹252 crore

GlaxoSmithKline Pharmaceuticals posted a 16% rise in net profit for the second quarter, reaching ₹252 crore, fueled by robust sales across various segments. Operating revenue increased to ₹1,010 crore for the September quarter, up from ₹957 crore in the same period last year.  

GlaxoSmithKline Q2 Results Highlights

• Revenue: ₹1,010 crore for the September quarter, up from ₹957 crore in the same period last year.
• Net Profit: Rose to ₹252 crore compared to net profit of ₹217 crore in the previous year.
• EBITDA: EBITDA grew 5% Y-o-Y to ₹522 crore whereas EBITDA margin went down by 50 basis points to 19.6%.
• Segment: Growth was particularly notable for key brands such as Augmentin and Nucala.

GlaxoSmithKline Management Commentary

The company announced that its board has approved a special interim dividend of ₹12 per equity share with a face value of ₹10 each.

"As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders. Our performance reflects our commitment to sustainable growth and innovation," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said.

The drugmaker also reported that its leading brands maintained their market share, aligning with overall category performance.

Stock Market Reaction

GSK Pharma shares closed 0.68% lower at ₹2,624.50 per share on the BSE. 

About GlaxoSmithKline

GSK plc (GSK) is a healthcare company specializing in the development, production, and commercialization of general and specialty medicines, as well as vaccines. Its product portfolio includes treatments for conditions such as HIV, respiratory diseases, cancer, immuno-inflammatory disorders, viral infections, central nervous system (CNS) disorders, metabolic and cardiovascular diseases, urogenital conditions, bacterial infections, dermatological issues, and rare diseases. The company is headquartered in Brentford, Middlesex, UK.